Erik Janssen

Erik Janssen has a diverse and extensive work experience. Erik started their career in 1997 as a Product Manager at Monsanto, where they focused on cardiovascular and CNS products. Erik then moved to Pharmacia as a Product Manager and CRM Project Manager for CNS. In 2001, Erik joined sanofi-aventis as a Product Manager in Oncology and later became the Business Unit Director for Oncology in Belgium and Luxembourg.

In 2005, Erik joined UCB, where they held various roles including Franchise General Manager for CNS in Belgium and Luxembourg, Director of CNS Operations Global, and Senior Director of Global Marketing for CNS/Epilepsy. Erik then became the General Manager for CNS in Germany and the European Champion for Vimpat, focusing on epilepsy.

From 2013 to 2019, Erik held Vice President positions at UCB, leading global patient solutions initiatives for Keppra and neurology. Erik'sresponsibilities involved providing innovative solutions, creating strategic plans, and ensuring patient empowerment.

Since 2017, Erik has also been involved in various board and executive positions, including being a Board Member at BlueHealth Innovation Center, a Managing Director at BlueHealth Innovation Fund, and a Partner at Reaction. Erik currently serves as a Board Member at BINGLI, Ceribell, Inc, and Eysz.

Overall, Erik Janssen has demonstrated expertise in the pharmaceutical industry, specifically in neurology, oncology, and patient solutions, and has extensive experience in leadership and strategic roles.

Erik Janssen earned a Master's degree in Chemistry from KU Leuven in 1991. Erik then pursued a Doctor of Science degree in Physical Chemistry from the same institution from 1991 to 1993. In 2018, Erik obtained an Executive MBA from Stanford University Graduate School of Business. Later, in 2022, they acquired two Postgraduate Degrees in Immunology from Harvard Medical School. Looking ahead to 2023, Erik plans to complete a Postgraduate Degree in Gene/Genetic Therapy at Harvard Medical School.